InvestorsHub101d agobullish
Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings BeatNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Investing.com101d agobullish
Bristol-Myers Squibb raises annual outlook as Q2 tops estimates; shares upReuters101d agoneutral
Bristol Myers raises 2026 forecast as Eliquis, newer medicines power resultsBarrons.com101d agoneutral
Bristol Myers Raises Earnings Guidance as Newer Drugs Drive Big Quarterly BeatBenzinga101d agoneutral
How To Earn $500 A Month From Bristol-Myers Squibb Stock Ahead Of Q2 EarningsStockStory102d agoneutral
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results TomorrowSimply Wall St.102d agoneutral
Higher Earnings Forecasts and Opdivo Combo Filing Might Change The Case For Investing In Bristol-Myers Squibb (BMY)24/7 Wall St.109d agoneutral
Bank of America Says the Fed Should Raise Rates Now: 4 Dividend Inflation-Resistant StocksReuters111d agobullish
Bristol Myers buys Nvidia's latest AI computing system for drug researchSimply Wall St.123d agoneutral
Bristol Myers Squibb (BMY) Stock Looks Cheap On Earnings But Mixed On ValueThe Wall Street Journal131d agoneutral
Genmab Shares Climb After Lymphoma Therapy Hits Goal in TrialBloomberg137d agobullish
A $30 Billion Cancer Breakthrough Is Under Threat From Global Conflicts